NetraMark Holdings Inc. Statement on U.S. Executive Order for Psychedelic Drug Research

NetraMark Holdings Inc. Statement on U.S. Executive Order for Psychedelic Drug Research

NetraMark Holdings Inc., a leading artificial intelligence company specializing in AI-powered precision analytics for clinical trials in the pharmaceutical industry, has issued a statement regarding the U.S. Executive Order "Accelerating Medical Treatments for Serious Mental Illness" released on April 18, 2026. The Executive Order aims to expedite research, evidence generation, and regulatory pathways for certain investigational psychedelic drugs, including ibogaine compounds.

The Executive Order outlines various initiatives to support the responsible development of psychedelic drugs, such as prioritizing FDA review for drugs with Breakthrough Therapy designation and promoting collaboration among the FDA, the Department of Health and Human Services (HHS), and the Department of Veterans Affairs to enhance evidence generation and clinical trial participation.

NetraMark Holdings Inc. is committed to leveraging artificial intelligence to revolutionize clinical trials and advance precision analytics in the pharmaceutical sector. The company's expertise in AI technology positions it at the forefront of innovation in the industry, driving advancements in drug development and patient care.